Pyxis Oncology, Inc. (PYXS) competitors & alternatives
Health Care · NASDAQ
Pyxis Oncology, Inc. (PYXS)'s top competitors and alternatives — its most similar public companies — include Pfizer (PFE), CELLDEX THERAPEUTICS INC (CLDX), JANUX THERAPEUTICS INC (JANX), Exelixis (EXEL), ALX ONCOLOGY HOLDINGS INC (ALXO), CANDEL THERAPEUTICS INC (CADL), Indaptus Therapeutics, Inc. (INDP), NEKTAR THERAPEUTICS (NKTR), CYTOMX THERAPEUTICS INC (CTMX), CRESCENT BIOPHARMA INC (CBIO), IMMUNOME INC (IMNM) and ADC THERAPEUTICS SA (ADCT). These are Pyxis Oncology, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PYXS competitors & alternatives
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
CELLDEX THERAPEUTICS INCCLDXHealth Care
A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin…
$34.77 (as of 2026-07-22) · market cap $2.7B
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.62 (as of 2026-07-22) · market cap $953M
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
ALX ONCOLOGY HOLDINGS INCALXOHealth Care
An early-stage immuno-oncology biotech advancing a next-generation CD47 blocker designed to restore macrophage tumor-killing when combined with targeted cancer…
$2.02 (as of 2026-07-22) · market cap $272M
-
CANDEL THERAPEUTICS INCCADLHealth Care
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic…
$10.09 (as of 2026-07-22) · market cap $739M
-
Indaptus Therapeutics, Inc.INDPHealth Care
A clinical-stage biotechnology company currently evaluating strategic options and potential business combinations to maximize shareholder value.
$2.64 (as of 2026-07-22) · market cap $300M
-
NEKTAR THERAPEUTICSNKTRHealth Care
A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
$69.32 (as of 2026-07-22) · market cap $2.4B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
IMMUNOME INCIMNMHealth Care
A clinical-stage oncology biotech advancing first-in-class and best-in-class targeted cancer therapies, including varegacestat for desmoid tumors and a…
$22.88 (as of 2026-07-22) · market cap $2.6B
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
Not quite? Describe exactly what you want →
Peers are Pyxis Oncology, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Pyxis Oncology, Inc. (PYXS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.